Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 811283 + Cytarabine in AML
NCT00632749Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2008
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BI 811283 in acute myeloid leukemia (AML), sponsored by Boehringer Ingelheim. Started May 2008; status: completed.
02
Drugs
BI 811283
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00632749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00632749.